Sie sind auf Seite 1von 24

Investor Presentation

October 2018
Disclaimer
FORWARD-LOOKING STATEMENTS
This presentation has been prepared solely for use at this meeting and is intended for investors and analysts only. The material is given in conjunction with an oral presentation
and should not be taken out of context. Unless the context requires otherwise, references to “ViewRay,” “the company,” “we,” “us” and “our” refer to ViewRay, Inc.

Except for historical information, ViewRay’s written and accompanying oral presentation may contain forward-looking statements, including statements about the overall industry,
including but not limited to: our current expectations of the market; growth drivers; future trends; demand for radiation oncology products and features; and innovation and
growth opportunities. Forward-looking statements also include, but are not limited to, statements about ViewRay’s: future orders; backlog or earnings growth; future financial
results; and market acceptance of ViewRay’s existing products, future products or technology. Words such as “could,” “anticipates,” “expects,” “outlook,” “intends,” “plans,”
“believes,” “seeks,” “vision,” “estimates,” “may,” “will,” “future,” “horizon,” “aiming,” “driving,” “target” (or variations of them) and similar statements, are forward-looking
statements. These types of statements express management’s beliefs based on the information available to us as of the date of this presentation, are subject to change and are
not guarantees of future performance. Forward-looking statements involve risks, uncertainties and assumptions that are difficult to predict and could cause ViewRay’s results to
differ materially from those presented. These risks, uncertainties and assumptions include, but are not limited to, changes in: the regulatory environment; global economics; trade
compliance requirements, duties or tariffs; third-party reimbursement levels; currency exchange rates; taxation, healthcare law, and product clearance requirements, as well as
those related to: adverse publicity about ViewRay and our products; our reliance on sole or limited source suppliers; our ability to commercialize our products successfully; the
impact of competitive products and pricing, and all other risks listed from time to time in the company’s filings with the Securities and Exchange Commission, which are
incorporated into this Forward-Looking Statements disclosure by this reference. We do not assume any obligation to update or revise the forward-looking statements in
ViewRay’s written or oral presentation, whether based on future events, new or additional information or otherwise.

ViewRay’s written and oral presentation does not constitute an offer to sell or the solicitation of an offer to buy, nor will there be any sale of ViewRay’s securities in any state or
other jurisdiction in which an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of that state or other jurisdiction.

MEDICAL ADVICE DISCLAIMER

ViewRay is a medical device manufacturer and cannot and does not recommend specific treatment approaches. Individual results may vary.

2
Driving a new standard of care in cancer
Powerful trend ➔ precise, minimally / non-invasive
therapies

ViewRay MRIdian® is a non-invasive radiation system


that provides surgery-like capabilities

Radiation therapy market large and ripe for


innovation

MRIdian offers clear advantages validated by early


clinical outcomes & KOL feedback

Broad market penetration requires focus on four key


workstreams:
▪ Commercial expansion
▪ Clinical evidence
▪ Technological innovation
▪ Operational infrastructure

3
Executive summary
Large Market Unique Technology
MRIdian MRIdian Linac >70 Scientific
8M Cancer cases diagnosed annually 1 FDA
Clearance
FDA
Clearance
Abstracts &
Publications
~$6.3B 2020 radiotherapy market (projected)
2

KOL & early Over 2000


clinical data Patients Treated
~1000 Linacs sold annually
2012 2018

Targeted
chemotherapies
Macro trends in oncology moving
Robotic
surgery towards more precise and less
invasive treatments
MRI-guided
radiotherapy

Precision Therapy Value Creation


1 Source: Globcan 2012
2 Markets & Markets, 2015 Radiotherapy Market Global Forecasts 2020 4
Estimated addressable market

~$6.3B
Initial targets
global radiotherapy market 1 Academic centers & early adopters
in 2020 (projected)

~$5Bn Estimated 350 – 400 replacements / year 2

Global Linac
$4.6B
~ Market ~$2 – 2.5B annual target market 2

global radiotherapy market


1
in 2015 MRIdian fits inside standard linac vaults
2

1 Markets & Markets, 2015 Radiotherapy Market Global Forecasts 2020


2 Internal reports and survey data
5
Disruptive, next generation technology
to better serve patients

Soft tissue
MRIdian potential benefits
visualization
MRIdian SmartVISION™
Optimized dose delivery to tumor

Shortened treatment course


On-table adaptive
treatments
MRIdian SmartADAPT™
Improved outcomes & reduced side effects

Targeting to preserve
healthy tissue
Improved quality of life
MRIdian SmartTARGET™

6
An image is worth a thousand words

MRIdian Diagnostic-Quality Conventional


Imaging IGRT Imaging
(MRIdian image courtesy of Amsterdam UMC) (https://www.varian.com/oncology/products/treatment-delivery/iterative-cone-beam-ct?cat=halcyon)

7
Disruptive, next gen technology
seamless integration of MRI and linac
CONE BEAM CT Linac MRIdian Linac
Potential limitations Potential benefits

Cannot see tumor boundaries Dose Dose Superior image quality


- Larger dose distribution area - Less impact to healthy tissue
TUMOR
TUMOR

Cannot see surrounding Real time imaging tracks


organs anatomy
- Unknowingly hitting organs at - Spares nearby organs &
risk permits higher dose to tumor

MR imaging
Cone Beam CT adds dose to - Does NOT add dose
patient
- Additional radiation exposure Imaging DURING
treatment
Poor image quality - No need for invasive
- Need for seed implants or fiducials markers

8
SmartVISION: Soft tissue visualization

Clear visualization drives more accurate dose delivery


9
SmartADAPT: On-table adaptive therapy
Non-adaptive RT: unfocused MRIdian: focused dose
dose

Real-time, on-table, adaptive radiotherapy (ROAR)


adjusts treatment for anatomical changes
10
SmartTARGET: Real-time tissue targeting

Soft tissue tracking during beam delivery


with automated beam control
11
Clinicians state…
“We can achieve truly ablative doses in the abdomen without also
achieving prohibitive levels of severe toxicity”
Lauren Henke, M.D. Washington University in St. Louis, Physics World Webinar July 2018

“Using ViewRay has changed our treatment options … we can treat


patients that in the past we would not…”
Salim Siddiqui, M.D. Ph.D. Henry Ford Hospital, ASTRO 2017 in-booth Presentation

“…for the first time we have made a difference in overall survival


with radiation therapy in pancreas cancer.”
Dr. Parag Parikh, M.D. Washington University in St. Louis, ASTRO 2017 in-booth Presentation

12
Early, promising results for the most challenging
cases
100%

2x Median
Survival 80%
MRIdian ROAR survival

% Overall Survival

Overall Toxicity
Increase 60%

40% Non-adaptive RT survival

0% Grade 3+
Toxicity
20%

0%
Non-adaptive RT toxicity

MRIdian ROAR toxicity

Months post-pancreatic cancer diagnosis

Launching Phase II Multi-institutional Trial: G3 Toxicity & Survival

Higher Maximum Biologic Effective Dose Utilizing Adaptive MRI Guided Radiation Therapy Improves Survival of Inoperable
Pancreatic Cancer Patients 13
Rudra S, Jiang N, Rosenberg S, Olsen J, Lagerwaard F, Bruynzeel A, Parikh P, Bassetti M, Lee P; ASTRO 2017
Clearly differentiated technology
MRIdian
SEE
Visualize the tumor and
surrounding organs in high-
definition

SHAPE
Adapt each treatment for daily
anatomical changes

STRIKE
Image soft tissue during beam-on
with automated beam control

SIZE
Fit through existing door openings
and into standard linac vaults

14
Clearly differentiated technology
Other MRgRT
MRIdian
Technologies
SEE
Visualize the tumor and surrounding
organs in high-definition

SHAPE Aspirational.
Adapt each treatment for daily NO on-table adaptive
anatomical changes
functionality

STRIKE
Image soft tissue during beam-on Real-time imaging but
with automated beam control NO gating beam control

SIZE
Fit through existing door openings Requires wall and/or ceiling
and into standard linac vaults removal AND new 1.5m trench

15
Clearly differentiated technology
MRIdian Other MRgRT Conventional IGRT
Technologies Linacs

SEE
Visualize the tumor and Non-diagnostic, low-
surrounding organs in high- contrast soft tissue imaging
definition

SHAPE Aspirational. Aspirational.


Adapt each treatment for NO on-table adaptive If you can’t see it,
daily anatomical changes functionality you can’t adapt to it

STRIKE
Image soft tissue during Real-time imaging but NO soft tissue imaging
beam-on with automated NO gating beam control during beam-on
beam control

SIZE Requires wall and/or ceiling


Fit through existing door removal AND new 1.5m
openings and into standard trench
linac vaults

16
A thought leader speaks…

“Just as the 2-dimensional x-rays we relied on in


the 1980s were replaced by CT-guided
radiotherapy, so will MR-guided radiation
technology render CT-guided radiation obsolete.”
- Daphne A. Haas-Kogan, MD
Chair of the Department of Radiation Oncology at Dana-Farber Cancer
Institute, Brigham and Women's Hospital and Boston Children's Hospital
“Opportunities Abound for Radiation Oncology in the Era of Personalized Medicine.”
RSNA Daily Bulletin. November 2017

17
How we drive growth…

Commercial Technological Operational


expansion innovation Clinical evidence infrastructure

Creating shareholder value

18
Commercial expansion
increase reach & resources to drive adoption

Primary target markets

United States
Increase direct
representation and
EMEA bolster distribution
network
Japan

19
Technological innovation
protect & extend technology leadership

Rich innovation pipeline &


patent estate

Speed
92
Issued patents
1, 2

Machine
vision

Biological
129
Patent applications
2

imaging
1 Licensed or owned (1 jointly owned)
2 Patent date effective 8/6/18 20
Clinical strategy
shaping care patterns, clinical guidelines & reimbursement policies

Aspirations
breast cancer

Fewer mastectomies
Improved cosmesis
Building clinical
prostate cancer compendium
Fewer prostatectomies
Reduce ED &
incontinence

lung cancer

Fewer lobectomies
Superior quality of life

21
Operational infrastructure
support & sustain growth

Build for growth &


global reach

Service & Education Back- Enhanced


support & training office capacity
support

22
Driving a new standard of care in cancer
Powerful trend ➔ precise, minimally / non-invasive
therapies

ViewRay MRIdian® is a non-invasive radiation system


that provides surgery-like capabilities

Radiation therapy market large and ripe for


innovation

MRIdian offers clear advantages validated by early


clinical outcomes & KOL feedback

Broad market penetration requires focus on four key


workstreams:
▪ Commercial expansion
▪ Clinical evidence
▪ Technological innovation
▪ Operational infrastructure

23